Edition:
India

Concordia International Corp (CXRX.OQ)

CXRX.OQ on NASDAQ Stock Exchange Global Select Market

0.50USD
11 Dec 2017
Change (% chg)

$-0.00 (-0.98%)
Prev Close
$0.50
Open
$0.50
Day's High
$0.52
Day's Low
$0.50
Volume
6,854
Avg. Vol
49,927
52-wk High
$3.52
52-wk Low
$0.45

Latest Key Developments (Source: Significant Developments)

UK CMA says it provisionally found that Concordia overcharged NHS by millions
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - UK Competition and Markets Authority -:‍CMA HAS PROVISIONALLY FOUND THAT CONCORDIA ABUSED ITS DOMINANT POSITION TO OVERCHARGE NHS BY MILLIONS FOR ESSENTIAL THYROID DRUG​.UK'S CMA ‍FINDINGS ARE PROVISIONAL AND THERE HAS BEEN NO DEFINITIVE DECISION THAT THERE HAS BEEN A BREACH OF COMPETITION LAW​.UK'S CMA ‍WILL CAREFULLY CONSIDER ANY REPRESENTATIONS FROM COMPANIES BEFORE DECIDING WHETHER LAW HAS IN FACT BEEN BROKEN​.  Full Article

Concordia International ‍comments on UK CMA statement of objections related to Liothyronine
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Concordia International Corp -:‍COMMENTS ON CMA STATEMENT OF OBJECTIONS RELATED TO LIOTHYRONINE; SAYS "DO NOT BELIEVE THAT COMPETITION LAW HAS BEEN INFRINGED​".‍WILL REVIEW CMA'S PRELIMINARY POSITION; CONTINUE TO WORK CO-OPERATIVELY WITH CMA AS IT PROCEEDS WITH ITS INVESTIGATION.​.  Full Article

Concordia International Q3 ‍reported revenue $154.6 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Concordia International Corp :Concordia International announces third quarter 2017 results.Concordia International Corp qtrly ‍reported revenue of $154.6 million, compared to $185.5 million for same period in 2016​.Concordia International Corp qtrly loss per share from continuing operations $1.36​.  Full Article

Concordia International seeks to realign capital structure under CBCA
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Concordia International Corp ::Concordia International Corp. takes next step to realign its capital structure by commencing proceedings under the Canada Business Corporations Act.Seeking to reduce its existing secured and unsecured debt obligations by more than $2 billion​.Intends to continue operating its business as usual during CBCA proceedings​.Company had approximately $340 million of cash on hand as of September 30, 2017​.Some ‍payments owed to unsecured lenders will not be paid as scheduled & are expected to be addressed as part of recapitalization.Proposed recapitalization transaction may result in dilution of outstanding common shares of company​.It is commencing a court proceeding under Canada Business Corporations Act​.Under CBCA process, Concordia's management will continue to lead day-to-day operations​.  Full Article

Concordia International-‍ UK CMA investigating into co's international segment
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Concordia International Corp :Concordia International-‍ UK CMA investigating issues related to UK pharmaceutical sector, co's international segment,certain products part of inquiry​.Concordia International -UK CMA ‍investigation at early, stage,CMA confirmed it has not reached conclusions if competition law been infringed​.  Full Article

Concordia International says ‍UK Competition and Markets Authority investigating pharma sector​
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Concordia International Corp :Says ‍UK competition and markets authority is investigating new issues in relation to UK pharmaceutical sector​.Says ‍that Concordia's International segment and certain of its products are part of CMA's inquiry​.Says ‍investigation is at an early, information-gathering stage​.Says ‍CMA's investigation includes matters that pre-date Concordia's ownership of international segment​.Concordia International says ‍CMA has confirmed that, at this time, it has not reached any conclusions on whether competition law has been infringed​.  Full Article

Concordia International announces communication with UK's CMA
Tuesday, 25 Oct 2016 

Concordia International Corp : Concordia International Corp announces communication with CMA . CMA's investigation includes matters that pre-date Concordia's ownership of international segment . CMA confirmed it has not reached a view as to whether there is sufficient evidence of any infringement for it to issue statement of objections .UK Competition and Markets Authority investigating issues related to UK pharmaceutical sector; co's international segment is part of inquiry.  Full Article

Concordia International closes senior notes offering, appoints Allan Oberman to board
Thursday, 13 Oct 2016 

Concordia International Corp : Concordia International announces closing of senior notes offering and appoints Allan Oberman to board of directors . Going forward, co will assess strategic alternatives .Following appointment of Allan Oberman to board effective October 14, 2016, the board will consist of six members.  Full Article

Concordia International announces pricing of offering of senior notes
Friday, 7 Oct 2016 

Concordia International Corp : Concordia International announces pricing of offering of senior notes . Says principal amount of notes is $350 million .Senior notes will bear an interest rate of 9.00 per cent per annum and will be issued at 100.00 per cent of their face value.  Full Article

Concordia International exercises option to defer portion of earn-out and provides update on strategic review
Monday, 3 Oct 2016 

CONCORDIA INTERNATIONAL CORP : Continues to evaluate its strategic alternatives . Continues to evaluate strategic alternatives including, but not limited to, various capital markets financing options . Expects payment of about £73.4 million (which includes a financing charge of up to £1.4 million) on or before february 1, 2017 . Concordia International exercises option to defer portion of earn-out and provides update on strategic review . Expects first payment of £72 million to be paid to cinven,other sellers of concordia's international segment on or about Dec. 19 .Concordia intends to use cash on hand generated by its international segment to make first payment of 72 million GBP.  Full Article

Drug firm Concordia overcharged Britain's health service with 6,000 percent price rise

LONDON Drug company Concordia overcharged Britain's health service millions of pounds for an essential thyroid drug by abusing its position as the only supplier, the country's Competition and Markets Authority said on Tuesday.